Consistent with these findings, the cotreatment of DLBCL-LN slices with blocking anti–PD-L1/2 antibodies enhanced the antitumor activity of glofitamab to a level comparable to that of combination FAP-4-1BBL/FAP-IL2v plus glofitamab — supporting the ability of FAP-targeted immunotherapies to counteract inhibitory signaling from FRCs (Supplemental Figure 10E). This evidence concerns the gene CD274 and diffuse large B-cell lymphoma.